MEREO BIOPHARMA (MREO)
(Real Time Quote from BATS)
$3.01 USD
+0.05 (1.69%)
Updated May 15, 2024 10:56 AM ET
2-Buy of 5 2
D Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MREO 3.01 +0.05(1.69%)
Will MREO be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for MREO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MREO
MEREO BIOPHARMA (MREO) Loses -12.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat
MREO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ultragenyx's (RARE) Preliminary 2023 Revenues Disappoint
Ultragenyx (RARE) Q3 Earnings and Revenues Miss Estimates
Ultragenyx (RARE) Q2 Loss Wider Than Expected, Revenues Beat
Other News for MREO
Analysts Offer Insights on Healthcare Companies: Daré Bioscience (DARE), Mereo Biopharma Group Plc (MREO) and Arcus Biosciences (RCUS)
Strong Buy Rating for Mereo Biopharma on Setrusumab’s Promising Phase 3 Progress and Financial Outlook
Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session